TheraRadar

Pharma Intelligence, Simplified

Landscape → Oncology

Renal Cell Carcinoma

544 clinical trials

287 active
/
544 total (since 2015)
136
Phase 1 Active
275 total
169
Phase 2 Active
308 total
33
Phase 3 Active
50 total
4
Phase 4 Active
10 total

Top Sponsors (Industry)

Sorted by active Active Done Failed
Merck 7 3 0
Bristol-Myers Squibb 5 5 2
Exelixis 5 0 1
AstraZeneca 4 0 0
Roche 3 2 3
Telix Pharmaceuticals (Innovations) Pty Limited 3 3 0
Arcus Biosciences, Inc. 3 1 0
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 3 1 0
GI Innovation, Inc. 3 0 0
NGM Biopharmaceuticals, Inc 3 0 0
HiFiBiO Therapeutics 2 0 1
Chongqing Precision Biotech Co., Ltd 2 0 0
Jiangsu Hansoh Pharmaceutical Co., Ltd. 2 0 0
OncoC4, Inc. 2 0 0
Pfizer 1 0 5
NCT03793166 ACTIVE NOT RECRUITING
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
National Cancer Institute (NCI) n=1,175
NCT06661720 RECRUITING
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Alliance for Clinical Trials in Oncology n=1,040
NCT03055013 ACTIVE NOT RECRUITING
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
National Cancer Institute (NCI) n=819
NCT05863351 ACTIVE NOT RECRUITING
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
ECOG-ACRIN Cancer Research Group n=472
NCT07011719 RECRUITING
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc. n=720
NCT07227402 RECRUITING
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Merck Sharp & Dohme LLC n=904
NCT02811861 ACTIVE NOT RECRUITING
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
Eisai Inc. n=1,069
NCT07383441 NOT YET RECRUITING
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
SWOG Cancer Research Network n=718
NCT03873402 ACTIVE NOT RECRUITING
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
Bristol-Myers Squibb n=437
NCT07000149 ACTIVE NOT RECRUITING
A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC
AstraZeneca n=1,116
NCT06726421 RECRUITING
Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)
Sun Yat-sen University n=252
NCT06500455 RECRUITING
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NRG Oncology n=269
NCT07338981 NOT YET RECRUITING
The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.
Guliz Ozgun n=142
NCT05770037 RECRUITING
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
Cancer Research UK n=30
NCT04810078 ACTIVE NOT RECRUITING
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
Bristol-Myers Squibb n=681
NCT07197580 NOT YET RECRUITING
Study of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
Telix Pharmaceuticals (Innovations) Pty Limited n=40
NCT03937219 ACTIVE NOT RECRUITING
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Exelixis n=855
NCT07165418 NOT YET RECRUITING
A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI
Peking University Cancer Hospital & Institute n=116
NCT04510597 RECRUITING
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
SWOG Cancer Research Network n=364
NCT04987203 ACTIVE NOT RECRUITING
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
AVEO Pharmaceuticals, Inc. n=343
NCT05678673 ACTIVE NOT RECRUITING
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
Exelixis n=317
NCT05796973 RECRUITING
Measuring Oncological Value of Exercise and Statin
Tampere University Hospital n=240
NCT03141177 ACTIVE NOT RECRUITING
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Bristol-Myers Squibb n=701
NCT05078047 RECRUITING
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
UNICANCER n=646
NCT05219318 ACTIVE NOT RECRUITING
Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors
University Hospital, Bordeaux n=22
NCT05043090 ACTIVE NOT RECRUITING
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
AstraZeneca n=148
NCT03592472 RECRUITING
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
Xynomic Pharmaceuticals, Inc. n=413
NCT06364631 RECRUITING
CARE1 Pragmatic Clinical Trial
Gustave Roussy, Cancer Campus, Grand Paris n=1,250
NCT05522231 ACTIVE NOT RECRUITING
Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
Hutchmed n=265
NCT06750419 RECRUITING
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
Telix Pharmaceuticals (Innovations) Pty Limited n=82
NCT03142334 ACTIVE NOT RECRUITING
Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)
Merck Sharp & Dohme LLC n=994
NCT06146777 NOT YET RECRUITING
Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy
First Affiliated Hospital, Sun Yat-Sen University n=468
NCT03288532 RECRUITING
Renal Adjuvant MultiPle Arm Randomised Trial
University College, London n=1,750
NCT07413120 COMPLETED
Efficacy and Safety of VasoClip® vs. WeckClip® for Robotic Urologic Surgery
Incheon St.Mary's Hospital n=40
NCT02853331 COMPLETED
Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)
Merck Sharp & Dohme LLC n=861
NCT07084909 WITHDRAWN
Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC
Lantheus Medical Imaging
NCT04394975 COMPLETED
Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer
Shanghai Junshi Bioscience Co., Ltd. n=421
NCT03260894 COMPLETED
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Incyte Corporation n=129
NCT04588246 TERMINATED
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology n=19
NCT06903260 COMPLETED
Robot-assisted Partial Nephrectomy With and Without Mixed Reality (REALITATEM Study)
Hospital Moinhos de Vento n=45
NCT03013946 TERMINATED
Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy
AIO-Studien-gGmbH n=121
NCT03849118 COMPLETED
89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study
Telix Pharmaceuticals (Innovations) Pty Limited n=300
NCT03024996 TERMINATED
A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Hoffmann-La Roche n=778
NCT03729245 TERMINATED
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
Nektar Therapeutics n=623
NCT02420821 COMPLETED
A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)
Hoffmann-La Roche n=915
NCT03408652 TERMINATED
Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapies
Centre Leon Berard n=1
NCT03693573 WITHDRAWN
A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma
Hoffmann-La Roche
NCT02535351 TERMINATED
Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano n=13
NCT01762592 WITHDRAWN
REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
Heidelberg Pharma AG
NCT02883153 COMPLETED
Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma
Radboud University Medical Center n=30

Data: ClinicalTrials.gov